TABLE 1.
Study characteristics of included trials
| First author | Year | Region | Type of study | Follow‐up | Participants | Female sex (%) | Treatment regimens |
|---|---|---|---|---|---|---|---|
| Wallentin 17 | 2009 | Asia and Australia, Europe, Middle East, America | multicenter | 12 months | 11 289 | 23.8 | ticagrelor vs. clopidogrel |
| Tang 18 | 2016 | Asia | two‐center | 6 months | 400 | 28.0 | ticagrelor vs. clopidogrel |
| Li 19 | 2018 | Asia | single‐center | 12 months | 442 | 21.7 | ticagrelor vs. clopidogrel |
| Cai 20 | 2015 | Asia | single‐center | 12 months | 120 | NA | ticagrelor vs. clopidogrel |
| Zeng 21 | 2017 | Asia | single‐center | 12 months | 204 | ticagrelor vs. clopidogrel | |
| Zhang 22 | 2017 | Asia | single‐center | 6 months | 181 | 49.0 | ticagrelor vs. clopidogrel |
| Motovska 16 | 2017 | Czech Republic | multicenter | 12 months | 1230 | NA | prasugre vs. ticagrelor |
| Patel 23 | 2018 | Asia | single‐center | 12 months | 1150 | NA | prasugre vs. ticagrelor |
| Schüpke 14 | 2019 | Europe | multicenter | 12 months | 4018 | 23.8 | prasugre vs. ticagrelor |
| Trenk 24 | 2012 | Europe and America | multicenter | 6 months | 423 | 27.4 | prasugre vs. clopidogrel |
| Wiviott 8 | 2007 | Asia and Africa, Europe, Middle East, America | multicenter | 15 months | 13 608 | 26.0 | prasugre vs. clopidogrel |
| Brener 25 | 2014 | Europe and America | multicenter | 12 months | 452 | 26.1 | prasugre vs. clopidogrel |
| Montalescot 26 | 2009 | NA | multicenter | 15 months | 3534 | 22.6 | prasugre vs. clopidogrel |
| Welsh 15 | 2019 | NA | multicenter | 12 months | 9932 | 23.8 |
prasugre vs. ticagrelor & ticagrelor vs. clopidogrel |